English
Alivus Life Sciences Q2 Results
- BSE: 543322
- NSE: ALIVUS
- ISIN: INE03Q201024
- Sector: Biotechnology & Drugs
BSE
942.65
38.30 (4.24%)
38.30 (4.24%)Volume3.63 K
Updated: Mon 17 Nov, 2025 | 14:15:35
NSE
942.3037.60 (4.16%)
37.60 (4.16%)Volume1.24 L
Updated: Mon 17 Nov, 2025 | 14:11:41
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
- Total Income₹587.98 Cr.(16.00%)
- Operating Profit₹160.73 Cr.(34.77%)
- Profit After Tax₹130.03 Cr.(36.42%)
- Operating Margin27.34%(16.18%)
Note: Comparison is on YoY basis
Quarterly - Alivus Life Sciences Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 427.25 | 446.60 | -4.33% | 387.61 | 10.22% |
| Depreciation/ Amortization | 18.44 | 17.06 | 8.03% | 15.09 | 22.14% |
| Operating Income | 160.73 | 155.25 | 3.54% | 119.27 | 34.77% |
| Net Income | 130.03 | 121.54 | 6.99% | 95.32 | 36.42% |
| Other Operating Expenses Total | 93.49 | 97.57 | -4.18% | 84.89 | 10.14% |
| Net Income Before Taxes | 174.14 | 162.98 | 6.84% | 127.46 | 36.63% |
| Total Revenue | 587.98 | 601.85 | -2.30% | 506.88 | 16.00% |
| Selling/ General/ Admin Expenses Total | 66.40 | 61.58 | 7.83% | 62.44 | 6.34% |
| Diluted Normalized EPS | 10.58 | 9.88 | 7.09% | 7.75 | 36.52% |